

DAFTAR PUSTAKA

- Abdel-Misih, S. R. Z. and Bloomston, M. (2010) 'Liver Anatomy', *Surgical Clinics of North America*. Elsevier Limited, 90(4), pp. 643–653. doi: 10.1016/j.suc.2010.04.017.
- Amirudin, R. 2014, 'Fisiologi dan Biokimia Hati', in Setiati, S. et al. (eds) *Buku Ajar Ilmu Penyakit Dalam Jilid II*. Edisi VI. Jakarta: Interna Publishing.
- Anis, M. and Irshad. (2011) 'Imaging of Hepatocellular Carcinoma : Practical Guide to Diffeerential Diagnosis', *liver.theclinics.com*, 15, pp. 335–352. doi: 10.1016/j.cld.2011.03.014.
- Ascha, M. S., Hanounch, I. A., Lopez, R., Tamimi, T. A., Feldstein, A.F., Zein, N.N. 2010, 'The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis', *Hepatology*, 51(6), pp. 1972–1978.
- Bai, D., Zhang, C., Chen, P., Jin, S. and Jiang, G. (2017) 'The prognostic correlation of AFP level at diagnosis with pathological grade , progression, and survival of patients with hepatocellular carcinoma', *Scientific Reports*. Springer US, (September), pp. 1–9. doi: 10.1038/s41598-017-12834-1.
- Bellentani, S., Baroni, G.S., Piscaglia, F., Tiribelli, C. 2016, 'Natural History of Nonalcoholic Steatohepatitis – Associated Hepatocellular Carcinoma', *Clinical Liver Disease*, 8(4), pp. 105–107.
- Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. 2012, 'Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions', *Seminars in Liver Disease*;32:348–359.
- Bruix, J. and Sherman, M. (2011) 'Management of hepatocellular carcinoma: An update', *Hepatology*, 53(3), pp. 1020–1022. doi: 10.1002/hep.24199.
- Budihusodo, U. 2014, 'Karsinoma Hati', in Setiati, S. et al. (eds) *Buku Ajar Ilmu Penyakit Dalam Jilid III*. Edisi VI. Jakarta: Interna Publishing.
- Carr BI. 2011. Tumors of the liver and biliary tree. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editor. *Harrison's principles of internal medicine*. New York: McGraw Hill; 544-50.
- Cartier V and Aube C, 2014. Diagnosis of hepatocellular carcinoma, *Diagnostic and Interventional Imaging*. 95(7–8): 709–719.

- Ellis, H. (2011) 'Anatomy of the liver', *Surgery*. Elsevier Limited, 29(12), pp. 589–592. doi: 10.1016/j.mpsur.2011.09.012.
- El-Serag HB. 2011. Hepatocellular carcinoma. *The New England Journal of Medicine*; 365:1118–1127.
- El-Serag, H. B., Marrero, J. A., Rudolph, L. and Reddy, K. R. (2008) 'Diagnosis and Treatment of Hepatocellular Carcinoma', *Gastroenterology*, 134(6), pp. 1752–1763. doi: 10.1053/j.gastro.2008.02.090.
- El-Serag, H. B. and Rudolph, K. L. (2007) 'Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis', *Gastroenterology*, 132(7), pp. 2557–2576. doi: 10.1053/j.gastro.2007.04.061.
- Farazi, P. A. and DePinho, R. A. (2006) 'Hepatocellular carcinoma pathogenesis: From genes to environment', *Nature Reviews Cancer*, 6(9), pp. 674–687. doi: 10.1038/nrc1934.
- Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ *et al*, 2009. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?. *Cancer*. 115(3): 616–623.
- Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A. and Pawlik, T. M. (2016) 'Hepatocellular carcinoma: From diagnosis to treatment', *Surgical Oncology*. Elsevier Limited, 25(2), pp. 74–85. doi: 10.1016/j.suronc.2016.03.002.
- Hall P, Johnny C. 2012. What is the real function of the liver 'function' test. *Ulster Medical Journal*; 81:30-36.
- Han KH, Kudo M, Ye SL, et al. 2011. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. *Oncology*; 81(Suppl 1):158–164.
- Hashimoto, E., Yatsuji, S., Tobari, M., Taniai, M., Torii, N., Tokushige, K. 2009, 'Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis', *Journal of Gastroenterology*, 44(SUPPL. 19), pp. 89–95.
- Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Mueller C, et al. 2014. The ART of decision making: re-treatment with TACE in patients with HCC. *Hepatology*. <http://dx.doi.org/10.1002/hep.26256>.
- Idée, J. M. and Guiu, B. (2013) 'Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review', *Critical Reviews in Oncology/Hematology*. Elsevier Ireland Limited, 88(3), pp. 530–549. doi: 10.1016/j.critrevonc.2013.07.003.

- Jemal A, Ward EM, Johnson CJ, et al. 2017. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. *Journal of the National Cancer Institute*; 109(9).
- Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H, 2015. Staging systems for hepatocellular carcinoma: Current status and future perspectives. *World Journal of Hepatology*. 7(3): 406–424.
- Liapi E and Geschwind JFH, 2011. Transcatheter Arterial chemoembolization for liver cancer: Is it time to distinguish conventional from drug-eluting chemoembolization?'. *CardioVascular and Interventional Radiology*. 34(1): 37–49.
- Longo, L. and Fauci, S. 2013, *Harrison's Gastroenterology and Hepatology*. 2nd ed. US: McGraw-Hill Education.
- Mahadevan, V. (2014) 'Anatomy of the Liver, Surgery. Elsevier Limited, <http://dx.doi.org/10.1016/j.mpsur.2014.10.004>
- Mc Evoy, S., Mc Carthy, C., Lavelle, L., et al. (2013) 'Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Disease', *Radiographic*;33:1653-1668. Doi: 10.1148/rg.336125104.
- Miller RP, Tadagavadi RK, Ramesh G, and Reeves WB, 2010. Mechanisms of cisplatin nephrotoxicity. *Toxins*. 2(11): 2490–2518.
- Mittal, S. and El-Serag, H. B. 2013, 'Epidemiology of HCC: Consider the Population', *Journal of Clinical Gastroenterology*, 47(0), pp. 1–10. doi: 10.1097/MCG.0b013e3182872f29.Epidemiology.
- Padhya, K. T., Marrero, J. A. and Singal, A. G. (2013) 'Recent advances in the treatment of HCC', *Current Opinion in Gastroenterology*, 29(3), pp. 285–292. doi: 10.1097/MOG.0b013e32835ff1cf.
- Sanyal, A. J., Yoon, S. K. and Lencioni, R. (2010) 'The Etiology of HCC and Consequences for Treatment', *The Oncologist*, 15(Supplement 4), pp. 14–22. doi: 10.1634/theoncologist.2010-S4-14.
- Shin, S. W. (2009) 'The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma', *Korean Journal of Radiology*, 10(5), p. 425. doi: 10.3348/kjr.2009.10.5.425.
- Sulaiman, H. A., Akbar, H.N., Lesmana, L.A., Noer, H.M.S.2007, *Buku Ajar Ilmu Penyakit Hati*. Jakarta: Jaya Abadi.

Sun HL, Ni JY, Jiang XY, Chen D, Chen YT, and Xu LF, 2017. The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT. *OncoTargets and Therapy*. 10: 3835–3842.

Suryaatmadja M. 2009. Pemeriksaan laboratorium uji fungsi hati. *Buletin ABC*.; 11:2-8.

Villanueva, A. (2019) ‘Hepatocellular Carcinoma’, *The New England Journal of Medicine*; 380;1450-62.doi: 10.1056/NEJMra1713263

Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY *et al*, 2005. Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. *Cancer Letters*. 221(2): 135–143.

Zhu RX, Seto WK, Lai CL, Yuen MF, 2016. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. *Gut and Liver*. 10(3): 332–339.